UroGen Pharma's GAAP loss for 3 months of 2022 was $28.392 million, up 9.5% from $25.935 million in the previous year. Revenue increased 81.2% to $13.564 million compared to $7.485 million a year earlier.
UroGen Pharma's GAAP loss for 3 months of 2022 was $28.392 million, up 9.5% from $25.935 million in the previous year. Revenue increased 81.2% to $13.564 million compared to $7.485 million a year earlier. 
investors.urogen.com
English (US) 